查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1972592

BETA-地中海型貧血檢測市場：按檢測類型、技術、檢體類型、最終用戶和分銷管道分類 - 全球預測（2026-2032年）

Beta Thalassemia Testing Market by Test Type, Technology, Sample Type, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，BETA-地中海貧血檢測市場價值將達到 5.2161 億美元，到 2026 年將成長至 5.7225 億美元，到 2032 年將達到 9.7102 億美元，複合年成長率為 9.28%。

主要市場統計數據
基準年 2025 5.2161億美元
預計年份：2026年 5.7225億美元
預測年份 2032 971,020,000 美元
複合年成長率 (%) 9.28%

全面概述BETA地中海貧血檢測的進展、臨床必要性以及影響診斷和治療路徑的相關人員的優先事項。

BETA-地中海型貧血檢測如今在遺傳醫學、公共衛生和臨床診斷的交叉領域發揮著至關重要的作用。分子技術的進步，以及新生兒和產前篩檢計畫的不斷擴展，使得該疾病從一種診斷異常轉變為可透過協調的檢測途徑進行有效管理的疾病。本節概述了推動檢測需求的臨床需求、將診斷整合到診療路徑中的實際操作情況，以及檢查室管理人員、臨床負責人和公共衛生官員的策略重點。

一場變革性的轉變正在透過創新、政策影響以及不斷變化的臨床和消費者期望，重新定義BETA-地中海貧血檢測的格局。

BETA-地中海型貧血的檢測領域正經歷著變革性的轉變，這主要得益於創新、法規的不斷改進以及醫療模式的轉變。次世代定序和基於CRISPR的檢測等分子技術正在提高診斷解析度，實現更精準的基因分型，並有助於制定標靶治療方案。同時，包括高效液相層析和毛細管電泳在內的傳統檢測平台也不斷改進，進而提升篩檢項目的通量和分析精度。

2025 年美國加徵關稅對 BETA-地中海貧血檢測的供應鏈、採購趨勢和臨床服務提供的累積影響。

美國加徵關稅和2025年貿易政策變化對BETA-地中海貧血檢測生態系統產生了累積的營運和策略影響。特種試劑、診斷設備和耗材的供應鏈變得更加複雜，迫使許多供應商和製造商調整籌資策略。為此，採購部門正在加快供應商多元化，並加強與國內製造商的對話，以確保檢測服務的連續性。

關鍵細分分析，以確定測試類型、技術、最終用戶、通路和檢體類型交叉並影響臨床路徑的領域。

基於細分市場的分析揭示了不同檢測類型、技術、終端用戶、通路和檢體類型之間存在的細微差異，並揭示了不同的市場機會和營運需求。按檢測類型分類，市場涵蓋帶因者篩檢、診斷檢測、新生兒篩檢、就地檢驗和產前篩檢。每個管道都有其獨特的營運需求，例如新生兒篩檢所需的高通量集中式工作流程，以及產前檢測和照護現場中對快速結果交付的需求。從技術面來看，診斷平台包括毛細管電泳、基於 CRISPR 的檢測、高效液相層析、微陣列分析、次世代定序和聚合酵素鏈鎖反應(PCR)。這些技術在解析度、儀器複雜性和實驗室面積方面存在差異，其應用受到臨床目標和資源可用性的影響。

區域趨勢和採用模式影響美洲、歐洲、中東和非洲以及亞太地區獲得BETA地中海貧血診斷服務的途徑。

區域趨勢對BETA-地中海貧血檢測的部署模式、監管協調和營運模式有顯著影響。在美洲，完善的新生兒篩檢基礎設施和一體化的檢查室網路為可擴展的項目提供了支持，但遍遠地區和不同支付方的可及性差異使得必須採取有針對性的干涉措施來覆蓋服務不足的人群。在歐洲、中東和非洲，不同的管理體制和偵測能力水準造成了部署曲線的複雜性。集中式標準實驗室和新興的照護現場舉措並存，跨國合作對於協調標準和培訓專案至關重要。在亞太地區，對基因組分析能力的快速投資以及對產前和新生兒篩檢日益成長的關注正在推動部署速度的加快，但對偏遠地區人群的後勤支援和檢體運輸網路的差異仍然是營運方面需要關注的問題。

企業間競爭、策略聯盟、技術授權和商業化方法影響BETA-地中海貧血檢測的競爭格局。

BETA-地中海型貧血檢測領域的競爭格局呈現出多元化的特點，既有成熟的診斷設備製造商，也有創新分子技術開發公司和專業服務供應商。設備製造商和試劑供應商致力於提升檢測靈敏度和易用性，而分子技術Start-Ups則專注於小型化、可重複檢測以及將檢測與臨床決策支援工具整合。合約實驗室和聯網診斷中心則透過提供檢驗的工作流程和外部品質評估服務來拓展服務範圍，為小規模診所和血庫提供必要的支援。

為製造商、臨床領導者、支付者和政策制定者提供實用建議，以加快可靠的檢測途徑並改善患者預後。

產業領導者應採取果斷行動，提升檢測的可靠性、患者可及性和營運韌性。首先，透過多元化供應來源，優先與擁有清晰的連續性計劃和檢驗的品質系統的製造商建立合作關係，降低地緣政治和關稅相關風險。其次，透過投資靈活的檢測平台，使檢測方法適應臨床需求，這些平台既能滿足新生兒篩檢的集中式高通量處理需求，也能滿足以地區為基礎篩檢的分散式照護現場需求。第三，積極與支付方和監管機構合作，建立能夠認可早期檢測和遺傳諮詢臨床價值的報銷框架和核准流程。

本文檔概述了嚴謹的調查方法，解釋了BETA-地中海型貧血檢測分析的資料來源、分析方法、檢驗程序和限制。

本分析整合了第一手訪談、二手文獻綜述和結構化檢驗，以確保分析的嚴謹性。第一手研究包括與實驗室主任、臨床遺傳學家、檢體採集專家和監管顧問的諮詢，以了解實際操作和策略重點。二級資訊來源包括同行評審出版物、專業學會指南和公開的監管文件，以梳理證據基礎並為技術性能提供背景資訊。研究結果透過跨資訊來源的三角驗證進行比對，以識別趨同趨勢並突出需要進一步研究的不確定領域。

簡明扼要的結論，整合了策略意義、營運重點和未來行動，供參與BETA-地中海貧血檢測和治療的相關人員參考。

總之，由於技術創新、醫療模式的演變以及對供應鏈韌性的日益重視，BETA-地中海貧血檢測正處於轉折點。高解析度分子檢測、不斷擴大的新生兒和產前篩檢專案以及分散式檢查方案的整合，為改善早期發現和患者管理創造了機會。然而，從檢體物流和檢查室間互通性到採購流程的複雜性等一系列營運挑戰，仍然是專案成功的關鍵。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 BETA-地中海貧血檢測市場（依檢測類型分類）

  • 攜帶者篩檢
  • 診斷測試
  • 新生兒篩檢
  • 即時檢測
  • 產前篩檢

第9章 BETA-地中海貧血檢測市場：依技術分類

  • 毛細管電泳
  • 基於 CRISPR 的檢測
  • 高效液相層析
  • 微陣列分析
  • 次世代定序
  • 聚合酵素鏈鎖反應

第10章：依檢體類型分類的BETA-地中海貧血檢測市場

  • 羊水
  • 血液樣本
  • 乾血斑

第11章 BETA-地中海貧血檢測市場：依最終用戶分類

  • 血庫
  • 診斷中心
  • 家庭醫療保健服務
  • 醫院
  • 專科診所

第12章 BETA-地中海型貧血檢測市場：依通路分類

  • 電子商務平台
  • 醫院收購
  • 線上管道
  • 藥房和零售

第13章 BETA-地中海型貧血檢測市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 BETA-地中海型貧血檢測市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 BETA-地中海型貧血檢測市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國BETA-地中海貧血檢測市場

第17章：中國BETA-地中海貧血檢測市場

第18章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • A. Menarini Diagnostics srl
  • Abbott Laboratories
  • BGI Genomics Co. Ltd.
  • Bio-Rad Laboratories Inc.
  • F. Hoffmann-La Roche Ltd.
  • Guangdong Hybribio Limited Corporation
  • Illumina Inc.
  • Mylab Discovery Solutions Pvt. Ltd.
  • Natera Inc.
  • PerkinElmer Inc.
  • QIAGEN NV
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.
  • Tosoh Corporation
Product Code: MRR-9A6A6F297442

The Beta Thalassemia Testing Market was valued at USD 521.61 million in 2025 and is projected to grow to USD 572.25 million in 2026, with a CAGR of 9.28%, reaching USD 971.02 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 521.61 million
Estimated Year [2026] USD 572.25 million
Forecast Year [2032] USD 971.02 million
CAGR (%) 9.28%

Comprehensive overview of beta thalassemia testing advances, clinical imperatives, and stakeholder priorities shaping diagnostics and care pathways

Beta thalassemia testing now occupies a pivotal role at the intersection of genetic medicine, public health, and clinical diagnostics. Advances in molecular methods, combined with expanding newborn and prenatal screening programs, have shifted the condition from a diagnostic curiosity to a disease managed through coordinated testing pathways. This section frames the clinical imperatives that drive testing demand, the operational realities of integrating diagnostics into care pathways, and the strategic priorities for laboratory managers, clinical leaders, and public health officials.

Clinicians require timely, accurate information to advise families, manage transfusion strategies, and evaluate candidates for curative therapies. Parallel to these clinical needs, laboratory networks are adapting workflows to accommodate a wider array of test types that span carrier screening, prenatal assessment, and newborn detection. Across these junctures, supply chain resilience, sample integrity, and interoperability of laboratory information systems are emerging as core determinants of reliable service delivery. The introduction of novel testing modalities is redefining what constitutes standard of care and is compelling stakeholders to rethink procurement, accreditation, and quality assurance practices.

Transformative shifts redefining the beta thalassemia testing landscape through innovation, policy influence, and evolving clinical and consumer expectations

The landscape for beta thalassemia testing is experiencing transformative shifts driven by innovation, regulatory evolution, and changing care models. Molecular technologies such as next-generation sequencing and CRISPR-based assays are expanding diagnostic resolution, enabling more precise genotyping and facilitating targeted therapeutic decisions. At the same time, improvements in conventional platforms-including high-performance liquid chromatography and capillary electrophoresis-are enhancing throughput and analytical precision for screening programs.

Concurrently, testing is moving closer to the point of care. Point-of-care testing solutions and dried blood spot sample workflows are enabling community-level screening and extending access into decentralized settings. This trend is paralleled by growing integration between diagnostic providers and electronic health ecosystems, which enhances result delivery and supports longitudinal patient management. Policy and payer environments are adapting, with reimbursement frameworks evolving to recognize the value of early detection and genetic counseling. Taken together, these shifts are prompting diagnostic laboratories, manufacturers, and health systems to prioritize agility, data integration, and cross-sector collaboration to capture clinical and population health benefits.

Cumulative effects of United States tariffs in 2025 on beta thalassemia testing supply chains, procurement dynamics, and clinical service delivery considerations

The imposition of tariffs and trade policy changes originating in the United States during 2025 has produced a cumulative set of operational and strategic effects on the beta thalassemia testing ecosystem. Supply chains for specialized reagents, diagnostic instruments, and consumables have experienced increased complexity, prompting many providers and manufacturers to reassess their sourcing strategies. In response, procurement teams have accelerated supplier diversification and intensified dialogue with domestic manufacturers to maintain continuity of testing services.

These dynamics have also altered procurement timing and capital planning. Clinical laboratories and health systems are extending inventory planning horizons and coordinating group purchasing efforts to mitigate exposure to tariff-driven cost variability. In addition, the tariffs have stimulated regional manufacturing conversations, encouraging investments in onshore or nearshore production of critical reagents and assay components. For research and development activities, the policy environment has emphasized the need for flexible design controls and modular supply chains that can tolerate episodic cross-border disruptions. Collectively, these adjustments affect testing availability timelines, contract negotiations, and strategic partnerships across manufacturers, distributors, and clinical laboratories.

Key segmentation insights revealing where test types, technologies, end users, distribution channels, and sample types intersect to influence clinical pathways

Segmentation-driven insight reveals nuanced opportunities and operational imperatives across test types, technologies, end users, distribution channels, and sample types. Based on Test Type, the market encompasses carrier screening, diagnostic testing, newborn screening, point-of-care testing, and prenatal screening; each pathway carries distinct operational requirements, from high-throughput centralized workflows for newborn screening to rapid turnaround needs for prenatal and point-of-care contexts. Based on Technology, diagnostic platforms include capillary electrophoresis, CRISPR-based testing, high-performance liquid chromatography, microarray analysis, next-generation sequencing, and polymerase chain reaction; these technologies vary in resolution, instrumentation complexity, and laboratory footprint, and their adoption is shaped by clinical objectives and resource availability.

Based on End User, key stakeholders range from blood banks to diagnostic centers, home healthcare services, hospitals, and specialty clinics; each end user imposes different volume, staffing, and quality control expectations, affecting how tests are validated and deployed. Based on Distribution Channel, procurement and access routes span e-commerce platforms, hospital purchases, online channels, and pharmacy & retail outlets; channel choice influences inventory management, lead times, and patient-facing access. Finally, based on Sample Type, testing methods are applied to amniotic fluid, blood sample, and dried blood spot matrices, each of which drives pre-analytic handling, transport logistics, and analytical constraints. Integrating these segmentation layers highlights that successful deployment requires alignment between technological capability, clinical workflows, and distribution strategies to ensure accuracy, accessibility, and sustainability.

Regional dynamics and adoption patterns across the Americas, Europe Middle East & Africa, and Asia-Pacific shaping access to beta thalassemia diagnostic services

Regional dynamics materially influence adoption patterns, regulatory alignment, and the operational models required to deliver beta thalassemia testing. In the Americas, established newborn screening infrastructure and consolidated laboratory networks support scalable programs, yet disparities in rural access and payer heterogeneity necessitate targeted interventions to reach underserved populations. In Europe, Middle East & Africa, diverse regulatory regimes and variable laboratory capacities create a mosaic of adoption curves; centralized reference laboratories coexist with nascent point-of-care initiatives, and cross-border collaborations are essential to harmonize standards and training programs. In Asia-Pacific, rapid investment in genomic capabilities and a rising emphasis on prenatal and newborn screening are driving accelerated adoption, though logistics for remote populations and variable sample transport networks remain an operational focus.

Across these regions, technology transfer, workforce development, and tailored reimbursement models are central levers for increasing testing reliability and reach. Differences in population genetics and screening priorities also require region-specific assay validation and counseling resources. Consequently, stakeholders must design implementation plans that reflect regional regulatory pathways, laboratory capacity, and health system financing mechanisms to translate diagnostic advances into measurable improvements in patient care and public health outcomes.

Competitive company dynamics, strategic collaborations, technology licensing, and commercialization approaches influencing the beta thalassemia testing competitive landscape

Competitive company dynamics in the beta thalassemia testing space are characterized by a mix of established diagnostic manufacturers, innovative molecular technology developers, and specialized service providers. Instrument makers and reagent suppliers invest in improving assay sensitivity and ease of use, while molecular startups focus on assay miniaturization, multiplexing, and integration with clinical decision support tools. Contract laboratories and networked diagnostic centers extend reach by offering validated workflows and external quality assessment services that smaller clinics and blood banks may rely upon.

Strategic collaborations and licensing partnerships are common, as hardware providers seek to embed proprietary consumables while software vendors supply analytics and data integration layers. Commercialization approaches emphasize modular solutions that can be scaled from centralized high-throughput labs to decentralized point-of-care deployments. Meanwhile, quality assurance, accreditation, and post-market surveillance capabilities differentiate organizations that can support regulated screening programs from those focused on research or niche clinical services. For buyers and partners, evaluating vendor roadmaps, supply chain resilience, and support ecosystems is critical when selecting partners for long-term diagnostic programs.

Actionable recommendations for manufacturers, clinical leaders, payers, and policymakers to accelerate reliable testing pathways and improve patient outcomes

Industry leaders should take decisive actions to strengthen testing reliability, patient access, and operational resilience. First, diversify supply sources and prioritize partnerships with manufacturers that have clear continuity plans and validated quality systems to mitigate geopolitical and tariff-related risks. Second, invest in flexible testing platforms that enable both centralized high-throughput processing for newborn screening and decentralized point-of-care solutions for community-based screening, thereby matching test modality to clinical need. Third, engage proactively with payers and regulators to develop reimbursement frameworks and approval pathways that recognize the clinical value of early detection and genetic counseling.

In addition, enhance laboratory interoperability by adopting common data standards and integrating diagnostic outputs into electronic health records, which supports care coordination and longitudinal outcome tracking. Prioritize workforce training and accreditation programs to ensure that end users-ranging from blood banks to specialty clinics-can maintain quality across different sample types, including amniotic fluid, venous blood, and dried blood spots. Finally, pursue collaborative research and public-private initiatives to validate novel technologies in real-world settings and to scale successful protocols across regions, thereby converting innovation into sustainable clinical impact.

Rigorous research methodology explaining data sources, analytical approaches, validation steps, and limitations informing this beta thalassemia testing analysis

This analysis synthesizes primary interviews, secondary literature review, and structured validation to ensure analytical rigor. Primary research included consultations with laboratory directors, clinical geneticists, procurement specialists, and regulatory advisors to capture operational realities and strategic priorities. Secondary sources encompassed peer-reviewed publications, guidelines from professional societies, and publicly available regulatory documentation to map the evidence base and contextualize technology performance. Findings were triangulated across sources to identify convergent trends and to flag areas of uncertainty requiring further investigation.

Analytical steps included mapping diagnostic pathways against segmentation dimensions, assessing supply chain vulnerabilities, and evaluating adoption enablers across regions. Quality assurance measures comprised peer review by domain experts, cross-validation of technical assertions, and sensitivity checks for qualitative judgments. Limitations are acknowledged: the study emphasizes structural and operational analysis rather than quantitative market estimations, and evolving policy landscapes may shift practical implications. Where appropriate, the report identifies topics that warrant ongoing monitoring and potential follow-up studies to maintain relevance as technologies and regulations evolve.

Concise conclusion synthesizing strategic implications, operational priorities, and next steps for stakeholders engaged in beta thalassemia testing and care

In summary, beta thalassemia testing is at an inflection point driven by technological innovation, evolving care models, and heightened attention to supply chain resilience. The convergence of high-resolution molecular assays, expanded newborn and prenatal screening programs, and decentralized testing options is creating opportunities to improve early detection and patient management. Nonetheless, operational challenges-ranging from sample logistics and laboratory interoperability to procurement complexity-remain critical determinants of program success.

Stakeholders should prioritize integrated strategies that align technology selection with end-user capabilities, regional regulatory contexts, and distribution channels. By focusing on quality assurance, workforce development, and resilient procurement practices, health systems can translate diagnostic advances into meaningful clinical and public health outcomes. The analysis underscores the importance of cross-sector collaboration and adaptive planning to ensure that innovations in testing equitably benefit patients and health systems across diverse geographic and operational settings.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Beta Thalassemia Testing Market, by Test Type

  • 8.1. Carrier Screening
  • 8.2. Diagnostic Testing
  • 8.3. Newborn Screening
  • 8.4. Point-Of-Care Testing
  • 8.5. Prenatal Screening

9. Beta Thalassemia Testing Market, by Technology

  • 9.1. Capillary Electrophoresis
  • 9.2. CRISPR-Based Testing
  • 9.3. High-Performance Liquid Chromatography
  • 9.4. Microarray Analysis
  • 9.5. Next-Generation Sequencing
  • 9.6. Polymerase Chain Reaction

10. Beta Thalassemia Testing Market, by Sample Type

  • 10.1. Amniotic Fluid
  • 10.2. Blood Sample
  • 10.3. Dried Blood Spot

11. Beta Thalassemia Testing Market, by End User

  • 11.1. Blood Banks
  • 11.2. Diagnostic Centers
  • 11.3. Home Healthcare Services
  • 11.4. Hospitals
  • 11.5. Specialty Clinics

12. Beta Thalassemia Testing Market, by Distribution Channel

  • 12.1. E-Commerce Platforms
  • 12.2. Hospital Purchases
  • 12.3. Online Channels
  • 12.4. Pharmacy & Retail

13. Beta Thalassemia Testing Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Beta Thalassemia Testing Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Beta Thalassemia Testing Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Beta Thalassemia Testing Market

17. China Beta Thalassemia Testing Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. A. Menarini Diagnostics s.r.l.
  • 18.6. Abbott Laboratories
  • 18.7. BGI Genomics Co. Ltd.
  • 18.8. Bio-Rad Laboratories Inc.
  • 18.9. F. Hoffmann-La Roche Ltd.
  • 18.10. Guangdong Hybribio Limited Corporation
  • 18.11. Illumina Inc.
  • 18.12. Mylab Discovery Solutions Pvt. Ltd.
  • 18.13. Natera Inc.
  • 18.14. PerkinElmer Inc.
  • 18.15. QIAGEN N.V.
  • 18.16. Sysmex Corporation
  • 18.17. Thermo Fisher Scientific Inc.
  • 18.18. Tosoh Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BETA THALASSEMIA TESTING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL BETA THALASSEMIA TESTING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES BETA THALASSEMIA TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA BETA THALASSEMIA TESTING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY CARRIER SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY CARRIER SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY CARRIER SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY NEWBORN SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY NEWBORN SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY NEWBORN SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY POINT-OF-CARE TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY POINT-OF-CARE TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY POINT-OF-CARE TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY CAPILLARY ELECTROPHORESIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY CAPILLARY ELECTROPHORESIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY CAPILLARY ELECTROPHORESIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY CRISPR-BASED TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY CRISPR-BASED TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY CRISPR-BASED TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY MICROARRAY ANALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY MICROARRAY ANALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY MICROARRAY ANALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY AMNIOTIC FLUID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY AMNIOTIC FLUID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY AMNIOTIC FLUID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY BLOOD SAMPLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY BLOOD SAMPLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY BLOOD SAMPLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY DRIED BLOOD SPOT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY DRIED BLOOD SPOT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY DRIED BLOOD SPOT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY BLOOD BANKS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY BLOOD BANKS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY BLOOD BANKS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY HOME HEALTHCARE SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY HOME HEALTHCARE SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY HOME HEALTHCARE SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY E-COMMERCE PLATFORMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY E-COMMERCE PLATFORMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY E-COMMERCE PLATFORMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY HOSPITAL PURCHASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY HOSPITAL PURCHASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY HOSPITAL PURCHASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY ONLINE CHANNELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY ONLINE CHANNELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY ONLINE CHANNELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY PHARMACY & RETAIL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY PHARMACY & RETAIL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY PHARMACY & RETAIL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS BETA THALASSEMIA TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS BETA THALASSEMIA TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS BETA THALASSEMIA TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA BETA THALASSEMIA TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA BETA THALASSEMIA TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA BETA THALASSEMIA TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA BETA THALASSEMIA TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA BETA THALASSEMIA TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA BETA THALASSEMIA TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE, MIDDLE EAST & AFRICA BETA THALASSEMIA TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE, MIDDLE EAST & AFRICA BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE, MIDDLE EAST & AFRICA BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA BETA THALASSEMIA TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA BETA THALASSEMIA TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE BETA THALASSEMIA TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE BETA THALASSEMIA TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE BETA THALASSEMIA TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 107. MIDDLE EAST BETA THALASSEMIA TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. MIDDLE EAST BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. MIDDLE EAST BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 110. MIDDLE EAST BETA THALASSEMIA TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. MIDDLE EAST BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 112. MIDDLE EAST BETA THALASSEMIA TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 113. AFRICA BETA THALASSEMIA TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. AFRICA BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. AFRICA BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 116. AFRICA BETA THALASSEMIA TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. AFRICA BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 118. AFRICA BETA THALASSEMIA TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC BETA THALASSEMIA TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC BETA THALASSEMIA TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC BETA THALASSEMIA TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. ASEAN BETA THALASSEMIA TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. ASEAN BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. ASEAN BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 129. ASEAN BETA THALASSEMIA TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. ASEAN BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. ASEAN BETA THALASSEMIA TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 132. GCC BETA THALASSEMIA TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. GCC BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. GCC BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 135. GCC BETA THALASSEMIA TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. GCC BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. GCC BETA THALASSEMIA TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPEAN UNION BETA THALASSEMIA TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPEAN UNION BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPEAN UNION BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPEAN UNION BETA THALASSEMIA TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPEAN UNION BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPEAN UNION BETA THALASSEMIA TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 144. BRICS BETA THALASSEMIA TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. BRICS BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. BRICS BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 147. BRICS BETA THALASSEMIA TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. BRICS BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. BRICS BETA THALASSEMIA TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 150. G7 BETA THALASSEMIA TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. G7 BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. G7 BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 153. G7 BETA THALASSEMIA TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. G7 BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 155. G7 BETA THALASSEMIA TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 156. NATO BETA THALASSEMIA TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. NATO BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. NATO BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 159. NATO BETA THALASSEMIA TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. NATO BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. NATO BETA THALASSEMIA TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. UNITED STATES BETA THALASSEMIA TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 164. UNITED STATES BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. UNITED STATES BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 166. UNITED STATES BETA THALASSEMIA TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. UNITED STATES BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 168. UNITED STATES BETA THALASSEMIA TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 169. CHINA BETA THALASSEMIA TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 170. CHINA BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. CHINA BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 172. CHINA BETA THALASSEMIA TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. CHINA BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 174. CHINA BETA THALASSEMIA TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)